Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
m |
|||
| Line 5: | Line 5: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]=== | ===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]=== | ||
| − | + | ==History of changes in PMDA indication== | |
| + | *2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive [[acute myeloid leukemia]]. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' AC220, ASP2689 | *'''Code names:''' AC220, ASP2689 | ||
| Line 17: | Line 18: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| − | [[Category:PMDA approved | + | [[Category:PMDA approved in 2019]] |
Revision as of 15:25, 8 June 2023
Note: this drug is only approved in Japan, at this time.
Mechanism of action
FLT3 inhibitor
Diseases for which it is used
FLT3+ AML
History of changes in PMDA indication
- 2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.
Also known as
- Code names: AC220, ASP2689
- Brand name: Vanflyta